Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncolytics Biotech (ONCY), Stryker (SYK) and Alker...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY), Stryker (SYK) and Alkermes (ALKS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Butterfly Network (BFLY), Alkermes (ALKS) and Connec...

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Alkermes (ALKS) and Connect Biopharma Holdings (CNTB)

Piper Sandler analyst David Amsellem reiterated a Buy rating on Alkermes today and set a price target of $43.00. Amsellem covers the Healthcare sec...

Alkermes (ALKS) Receives a Buy from Piper Sandler

In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Alkermes, with a price target of $53.00. According to TipRanks...

Mizuho Securities Sticks to Their Buy Rating for Alkermes (ALKS)

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Alkermes today and set a price target of $53.00. Ear covers the Healthcare sector, focu...

Mizuho Securities Reaffirms Their Buy Rating on Alkermes (ALKS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD) and Alkermes (ALKS) with bull...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALKS	$48.15	+4.63%	1.20M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALKS	$48.15	+4.6%	1.20M
3
4
5
6

ALKS

ALKS

Get Alkermes plc Data in Excel

Get Alkermes plc Data in Excel